Autres langues Acadia Pharmaceuticals Inc.

Actions

ACAD

US0042251084

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
20,53 ^USD	-0,73%		-22,22%	-23,14%

03:26	Neuren estime que l’autorisation d’un brevet américain pourrait prolonger la protection de Trofinetide jusqu’en 2041	MT
28/09	Acadia Pharmaceuticals obtient de l’Office américain des brevets et des marques l’acceptation de sa demande de brevet sur la posologie du trofinétide	MT

Autres langues

03:26	Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041
28/09	Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent
28/09	Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
28/09	Acadia Pharmaceuticals Inc. Announces Allowance of U.S. Patent Application Covering Weight-Banded Dosing of Trofinetide
25/09	Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says
25/09	Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says
24/09	Sector Update: Healthcare Stocks Advance Late Afternoon
24/09	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions Before US-China Talks
24/09	Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
24/09	Acadia Pharmaceuticals Inc. Announces Phase 3 Enabling Topline Results from Phase 2 Radiant Study of Remlifanserin for the Treatment of Alzheimer?S Disease Psychosis
24/09	ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint
24/09	Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
25/08	EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu
25/08	Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug
24/08	Acadia Pharmaceuticals Inc. Receives European Commission Approval For DAYBU For Treatment Of Neurobehavioral Symptoms Of Rett Syndrome
24/08	ACADIA Pharmaceuticals Wins EU Approval for Rett Syndrome's Drug
24/08	European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
24/08	La Comisión Europea aprueba DAYBU® (trofinetida) como el primer y único tratamiento para los síntomas neuroconductuales del Síndrome de Rett en la Unión Europea
24/08	De Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie
24/08	Europäische Kommission erteilt Zulassung für DAYBU® (Trofinetid) als erste und einzige Therapie für neurobehaviorale Symptome des Rett-Syndroms in der Europäischen Union
10/08	Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says
05/08	ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says
05/08	Neuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%
04/08	ACADIA Pharmaceuticals Q2 Earnings, Revenue Rise; Lifts 2026 Outlook
04/08	Earnings Flash (ACAD) ACADIA Pharmaceuticals Posts Q2 EPS $0.18, vs. FactSet Est of $0.06